NCT05503940

Brief Summary

Dyspepsia is a very common gastrointestinal disease. Some medications, were associated with higher frequent incidences of dyspepsia, including non-steroid anti-inflammatory drugs (NSAIDs), Bisphosphonates, Tetracyclines, et al. Multiple medications were suggested to be strongly relate to adverse drug events (ADEs), adverse drug reactions (ADRs), drug-drug interactions, and drug-disease interactions, which may cause gastrointestinal(GI) dysfunction or injury to the GI mucosa. However, it was unclear whether multiple medications was associated with more severe symptoms of dyspepsia and dyspepsia-based score systems.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
600

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2022

Geographic Reach
1 country

4 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2022

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

August 15, 2022

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 17, 2022

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2023

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2024

Completed
Last Updated

September 2, 2022

Status Verified

August 1, 2022

Enrollment Period

1.6 years

First QC Date

August 15, 2022

Last Update Submit

August 30, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • The rate of patients with severe dyspepsia judged by patients

    Patients rated the severity of dyspepsia as mild, moderate, and severe by themselves

    1 day

Secondary Outcomes (9)

  • Global Overall Symptom score (GOSS)

    1 days

  • Functional dyspepsia

    1 days

  • organic upper gastrointestinal (GI) diseases.

    1 day

  • subtypes of functional dyspepsia

    6 months

  • Short Form of Nepean Dyspepsia Index (SF-NDI)

    1 day

  • +4 more secondary outcomes

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients aged ≥ 18 years old who met broad criteria of dyspepsia were eligible for our study.

You may qualify if:

  • aged ≥18 years old
  • Patients who met broad criteria of dyspepsia

You may not qualify if:

  • organ failure defined by Marshall standard
  • severe psychiatric illnesses
  • suspected or identified bowel obstruction
  • known malignancy
  • pregnancy or lactation
  • unable to provide consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

Lanzhou University Second Hospital

Lanzhou, Gansu, China

NOT YET RECRUITING

The Second Affiliated Hospital of Xi'an Jiaotong University

Xi'an, Shaanxi, 710032, China

NOT YET RECRUITING

Xijing 986 Hospital

Xi'an, Shaanxi, 710032, China

NOT YET RECRUITING

Xijing Hospital of Digestive Diseases

Xi'an, Shaanxi, 710032, China

RECRUITING

MeSH Terms

Conditions

Dyspepsia

Condition Hierarchy (Ancestors)

Signs and Symptoms, DigestiveSigns and SymptomsPathological Conditions, Signs and Symptoms

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
professor

Study Record Dates

First Submitted

August 15, 2022

First Posted

August 17, 2022

Study Start

June 1, 2022

Primary Completion

December 31, 2023

Study Completion

June 1, 2024

Last Updated

September 2, 2022

Record last verified: 2022-08

Locations